Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00035932 · ClinicalTrials.gov registry record · Phase 3

Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV

A Phase 3 study of HIV Infections, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 3
Development phase
571
Enrollment target
20
Study locations

NCT00035932 is a Phase 3 study of HIV Infections that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 571 participants, above the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (28% higher). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00035932, a Phase 3 study of HIV Infections, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 3
Development phase
571 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to learn how well atazanavir (ATV) works in combination with ritonavir (RTV) or saquinavir (SQV) with tenofovir (TDF) and a nucleoside to reduce the viral load of treatment experienced subjects with human immunodeficiency virus (HIV). There is a comparison arm with lopinavir (LPV)/RTV and TDF and a nucleoside.

Conditions Studied

HIV Infections

Interventions

  • DRUG Atazanavir + ritonavir + tenofovir + nucleoside
  • DRUG Atazanavir + saquinavir + tenofovir + nucleoside
  • DRUG Lopinavir/ritonavir + tenofovir + nucleoside

Study Locations (20)

Florida

  • - Altamonte Springs
  • - Fort Lauderdale
  • - Fort Lauderdale
  • - Miami Beach
  • - Orlando

California

  • - San Francisco
  • - Torrance

Massachusetts

  • - Brookline
  • - Fall River

New Jersey

  • - East Orange
  • - Newark

New York

  • - Buffalo
  • - Manhasset

Colorado

  • - Boulder

Georgia

  • - Decatur

Hawaii

  • - Honolulu

Trial Details

FieldValue
Enrollment Target 571 participants
Start Date 2001-11
Est. Completion 2009-03
Phase Phase 3

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00035932

The ClinicalTrials.gov registry entry for NCT00035932 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 571 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (28% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 3 interventions - of which Atazanavir + ritonavir + tenofovir + nucleoside is the first listed.

NCT00035932 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, California, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00035932 about?

NCT00035932 is a clinical study titled "Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV". The purpose of this study is to learn how well atazanavir (ATV) works in combination with ritonavir (RTV) or saquinavir (SQV) with tenofovir (TDF) and a nucleoside to reduce the viral load of treatment experienced subjects with human immunodeficiency virus (HIV). There is a comparison arm with lopin...

What is the current status of trial NCT00035932?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 571 participants. The study started on 2001-11. Estimated completion is 2009-03.

What conditions does trial NCT00035932 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00035932?

The interventions under investigation include: Atazanavir + ritonavir + tenofovir + nucleoside (DRUG), Atazanavir + saquinavir + tenofovir + nucleoside (DRUG), Lopinavir/ritonavir + tenofovir + nucleoside (DRUG).

Who is sponsoring clinical trial NCT00035932?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00035932 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.